CA2257084A1 - Traitement des troubles du metabolisme des lipides et du metabolisme du glucose a l'aide d'antagonistes de la dopamine et de la seratonine - Google Patents

Traitement des troubles du metabolisme des lipides et du metabolisme du glucose a l'aide d'antagonistes de la dopamine et de la seratonine Download PDF

Info

Publication number
CA2257084A1
CA2257084A1 CA002257084A CA2257084A CA2257084A1 CA 2257084 A1 CA2257084 A1 CA 2257084A1 CA 002257084 A CA002257084 A CA 002257084A CA 2257084 A CA2257084 A CA 2257084A CA 2257084 A1 CA2257084 A1 CA 2257084A1
Authority
CA
Canada
Prior art keywords
agonist
dopamine agonist
dopamine
agonists
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002257084A
Other languages
English (en)
Inventor
Anthony H. Cincotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ergo Research Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2257084A1 publication Critical patent/CA2257084A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles méthodes améliorées qui permettent la régulation chez un mammifère d'au moins une des caractéristiques suivantes: poids du corps, teneur en graisses du corps, consommation d'aliments, métabolisme des lipides et métabolisme du glucose. L'administration d'un agoniste D1 ou D2 ou de ces deux agonistes, le matin, en combinaison avec l'administration d'un agoniste du sous-type du récepteur 5HT1B la nuit, se traduit par la réduction de la consommation de nourriture, du poids du corps, des taux de glucose sérique et de la teneur totale en graisses du corps.
CA002257084A 1996-06-06 1997-06-06 Traitement des troubles du metabolisme des lipides et du metabolisme du glucose a l'aide d'antagonistes de la dopamine et de la seratonine Abandoned CA2257084A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1920996P 1996-06-06 1996-06-06
US60/019,209 1996-06-06
PCT/US1997/010838 WO1997046239A1 (fr) 1996-06-06 1997-06-06 Traitement des troubles du metabolisme des lipides et du metabolisme du glucose a l'aide d'antagonistes de la dopamine et de la seratonine

Publications (1)

Publication Number Publication Date
CA2257084A1 true CA2257084A1 (fr) 1997-12-11

Family

ID=21792005

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002257084A Abandoned CA2257084A1 (fr) 1996-06-06 1997-06-06 Traitement des troubles du metabolisme des lipides et du metabolisme du glucose a l'aide d'antagonistes de la dopamine et de la seratonine

Country Status (4)

Country Link
JP (1) JP2000513337A (fr)
AU (1) AU3408097A (fr)
CA (1) CA2257084A1 (fr)
WO (1) WO1997046239A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
CN1283116A (zh) * 1997-10-28 2001-02-07 先灵公司 降低哺乳动物嗜欲的方法
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2008014299A2 (fr) * 2006-07-27 2008-01-31 Allergan, Inc. Méthodes et compositions utiles pour le traitement de l'hyperlipidémie
WO2012177962A1 (fr) 2011-06-23 2012-12-27 Map Pharmaceuticals, Inc. Nouveaux analogues de fluoro-ergoline
WO2013095707A1 (fr) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Nouveaux dérivés d'iso-ergoline
EP2793583A4 (fr) 2011-12-21 2015-08-12 Map Pharmaceuticals Inc Nouveaux composés neuromodulateurs
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
CN107428745A (zh) 2015-01-20 2017-12-01 Xoc制药股份有限公司 麦角灵化合物及其用途
CA2974113A1 (fr) 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc. Composes d'isoergoline et leurs utilisations
JP2020522504A (ja) 2017-06-01 2020-07-30 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ 多環式化合物およびそれらの用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783469A (en) * 1986-03-07 1988-11-08 Meier Albert H Method of inhibiting body fat stores
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
ES2061953T3 (es) * 1988-11-24 1994-12-16 Akzo Nv Un procedimiento para preparar una composicion farmaceutica.

Also Published As

Publication number Publication date
JP2000513337A (ja) 2000-10-10
WO1997046239A1 (fr) 1997-12-11
AU3408097A (en) 1998-01-05

Similar Documents

Publication Publication Date Title
US5877183A (en) Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
US6855707B2 (en) Method for the treatment of lipid and glucose metabolism disorders
Carani et al. Effects of androgen treatment in impotent men with normal and low levels of free testosterone
US5626860A (en) Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5668155A (en) Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
EP1776955B1 (fr) Therapie de troubles du metabolisme des lipides et du glucose et composition afferente
CA2257084A1 (fr) Traitement des troubles du metabolisme des lipides et du metabolisme du glucose a l'aide d'antagonistes de la dopamine et de la seratonine
WO1997041873A9 (fr) Therapie de troubles du metabolisme des lipides et du glucose et composition afferente
CA2152508A1 (fr) Methode pour determiner le taux quotidien de prolactine
US5830895A (en) Methods for the determination and adjustment of prolactin daily rhythms
Vaughan et al. Metabolic and thyroidal consequences of melatonin administration in mammals
JP2007291139A (ja) 脂質及びグルコースの代謝疾患治療剤及び組成物
ARNOLD et al. Serotonin receptor antagonists block a natural, short term surge in serum growth hormone levels
Grossman et al. Alpha2-adrenoceptor agonists stimulate growth hormone secretion but have no acute effects on plasma cortisol under basal conditions
CZ155494A3 (en) The use of dopamine and prolactin stimulator antagonist for preparing a pharmaceutical preparation and the pharmaceutical preparation itself
Smythe et al. Mechanisms of 5-hydroxy-L-tryptophan-induced adrenocorticotropin release: a major role for central noradrenergic drive
AU3101395A (en) Improved methods for the determination and adjustment of prolactin daily rhythms
WO1998017306A1 (fr) Procede servant a augmenter les niveaux d'insuline du sang chez les mammiferes
Wiersinga et al. The effect of α-and β-adrenoceptor agonists and antagonists on the in vitro conversion of thyroxine into triiodothyronine
Yatham et al. Role of serotonin3 receptors in prolactin release induced by electroconvulsive therapy: A study with ondansetron

Legal Events

Date Code Title Description
FZDE Discontinued